Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
By Bhanvi Satija
(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.
About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite.
The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock.
Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.
Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren.
Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss.
Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval.
"We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said.
Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said.
Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds
Faecal microbial transplants (FMT), which involve transferring stool samples from a healthy gut to someone else's colon, have yielded some impressive medical results in the past. Researchers have seen promising signs of its ability to address irritable bowel syndrome, Crohn's disease, and even early Parkinson's (though this benefit only seemed to be short-lived) and other neurological issues. It has a 90% success rate for treating a bacterium related to diarrhoea, the BBC reported. But a new study published in the journal Cells has raised questions about the long-term safety of FMT treatments, suggesting that a bacterial 'mismatch' may cause problems with the patient's immune system and metabolism down the line. The scientists only found the link in mice and were not able to say how the changes they witnessed in the animals might manifest in people. They gave antibiotics to mice to interrupt their gut's normal microbiome, and then treated them with FMT and monitored them for one to three months. Often, the researchers discovered, the gut bacteria ended up in the wrong part of the gut – 'regional mismatches' – that seemed to disrupt the gut. After taking biopsies of the liver and gut, the scientists found that some genes, especially those related to the immune system and metabolism, had changed. Speaking to the University of Chicago, the study's lead author, researcher Orlando 'Landon' DeLeon said: 'I think it's a bit of a wake-up call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there. 'There are microbes along the entire intestinal tract, and we just study predominantly the last third of it (the colon),' he added. 'So how can you expect an FMT, with microbes from a third of the intestinal tract at the end of it, to fix the rest of the intestine?' No. This study was done on mice, which have different anatomies from us; even though the scientists found genetic changes in the liver and gut, they are not sure yet how those changes might affect even the mouse, never mind us. The study's researchers, however, still think it's a good idea to pursue 'omni-microbial transplants,' or OMT, writing in their paper: 'regional microbial mismatches after FMTs can lead to unintended consequences and require rethinking of microbiome-based interventions.' OMTs would include more bacteria from a greater area of the gut, theoretically increasing the likelihood that the correct ones will go to the right spot. Gut Health Discovery Could Help Future Parkinson's Diagnoses Let's Settle This – Is The Viral 'Puff Vs Pit' Armpit Health Check Actually Helpful? New Study Finds The Exact Age Bad Health Habits Catch Up To You
Medscape
41 minutes ago
- Medscape
Can Behavioral Support Enhance CGM Use in T1D?
TOPLINE: Behavioral support for first-time users of a continuous glucose monitoring (CGM) device showed no significant difference in reduction of A1c levels compared with CGM alone in the management of type 1 diabetes (T1D). Adults in both groups reported reduced diabetes distress. METHODOLOGY: Automated insulin delivery systems are the standard of care for adults with T1D, and using them requires both an insulin pump and a CGM device. A randomized controlled trial was conducted to assess the use of CGM among 134 adults with T1D who had not previously used CGM (mean age, 35 years; 77% women; 55% not using an insulin pump) who were recruited from clinics and T1D organizations across the United States. Participants were randomly assigned to one of two groups: one received CGM alone and the other received CGM plus the ONBOARD behavioral intervention, both for 3 months. The ONBOARD intervention included four 60-minute virtual, 1:1 biweekly sessions to address barriers related to wearing the device, data management, social concerns, and trust. Changes in A1c levels and diabetes distress scores were evaluated using t-tests and linear mixed-effect models over 12 months. TAKEAWAY: At 12 months after initiating CGM, 80% of participants in the ONBOARD group and 71% in the CGM-only group reported using CGM. Both the CGM-only and ONBOARD groups showed significant reductions in A1c levels (P < .05), with no significant difference between the groups. Participants in both groups experienced significant and clinically meaningful decreases in diabetes distress (P < .001). The CGM-only group showed greater reductions in diabetes distress than the ONBOARD group at 3 months; reductions were similar between groups at 6 and 12 months. IN PRACTICE: "Findings highlight benefits of introducing CGM on diabetes management and diabetes distress for adults with T1D. Most participants were still using CGM 12 months after initiating use through the study, indicating durable uptake," the authors write. SOURCE: The study was led by Molly L. Tanenbaum, PhD, Stanford University School of Medicine, California. The poster will be presented on June 23 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center, Chicago, Illinois. LIMITATIONS: No study limitations were discussed in the abstract. DISCLOSURES: One author disclosed consulting roles with Sanofi and Havas Health, an advisory role with MannKind Corporation, and receiving research support from embecta. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Bloomberg
42 minutes ago
- Bloomberg
Health Insurers Pledge to Reduce Red Tape for Care Approval
A group of the nation's largest health insurers agreed to streamline preapprovals for medical care, addressing a controversial process that can result in delays or outright denials of patient treatment. The insurers pledged to reduce the number of procedures that require so-called 'prior authorization,' standardize processes across different plans and ensure 80% of electronic approvals for medical claims are answered in real time. The voluntary changes, which would be implemented on varying timelines by 2027, are set to be formally announced on Monday.
